Targeting Behavior

In this article, we discuss how medical providers should engage in better communication with patients to improve outcomes.

Recent Content

A multicenter, double-blind, placebo-controlled, phase 3 vaccine trial is now underway for post-resection melanoma patients with a high risk of recurrence.

Because of the high mutation rate in melanoma cells, cancer drugs have been developed to help target these signaling pathways that stimulate such rapid growth. While many of these drugs have proven to be successful, resistance to these same drugs can also occur.

When it comes to cutaneous malignant melanoma (CMM), BRAFV600E is a common mutation found in approximately 50% of cases. Currently, BRAF mutations are detected by using DNA tests, but there may be an alternative assay that's less expensive, requires less tissue, more efficient, and thought to be more sensitive.

A 67-year-old man presents with hematuria and a kidney mass found on imaging. After further evaluation, a biopsy is performed. What is your diagnosis?

Of the 39 advanced gastric cancer patients treated with the immunotherapy antibody, pembrolizumab (Keytruda, Merck), 22.2% had an objective response. The median time to response was 8 weeks and the median progression-free survival (PFS) was 1.9 months

The PD-1 inhibitor nivolumab increased progression-free and overall survival compared with chemo in patients with previously untreated metastatic melanoma.

No difference in anxiety was found among patients with non-Hodgkin lymphoma who were assigned to maintenance rituximab compared with those patients who were assigned to rituximab re-treatment upon disease progression, results of a recent study show.

By clicking Accept, you agree to become a member of the UBM Medica Community.